Congratulations to Joseph E. Eid and his team for the Dragonfly Therapeutics, Inc. recent partnership with Gilead Sciences.
Drug Name : DF-1001
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly's TriNKET technology platform and Dragonfly's lead clinical asset, with Trodelvy, Gilead's Trop-2-directed antibody drug conjugate (ADC), in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC).
"DF1001 is the first of eight Dragonfly-developed drugs in the clinic and has shown clinical benefit in mBC, NSCLC and colorectal cancer (CRC) in a heterogeneous Phase 1 population with 22% RECIST responders and 39% clinical benefit in mBC patients at active dose levels, with no DLTs, even in a heavily-pre-treated population," said Joseph Eid, Dragonfly President of R&D. "It has been demonstrated to be well tolerated across all dose levels in the Phase 1 study as monotherapy, and pharmacodynamic activity was demonstrated in 28/42 (67%) paired biopsies from 0.5-15mg/kg, where increase in CD8 and NK cell infiltration was observed consistent with preclinical models and supporting the TriNKET immune modulating MoA. Our preclinical work has shown the powerful combinatorial effect of TriNKETs with ADCs, and highlighted the potential benefits to patients of using Gilead's Trodelvy in combination with DF1001."
We are thrilled to announce a new clinical collaboration with #Gilead, combining DF1001, our HER-2 immune engager, with Trodelvy, Gilead's Trop-2-directed antibody drug conjugate (ADC), for two cancer indications. https://lnkd.in/e4TQwHbC
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications
prnewswire.com
CDO at Therabest Co., Ltd.
6moOne of the collaborations in IO! Looking forward to seeing great results!